Anti-hapten antibody problems
Haptens are small molecules bound to a larger carrier protein to enable antibody discovery. This often yields antibodies with poor affinity and selectivity. Here we discuss why this is…
Haptens are small molecules bound to a larger carrier protein to enable antibody discovery. This often yields antibodies with poor affinity and selectivity. Here we discuss why this is…
Finding the right affinity ligand pair is a bottleneck in immunoassay development where the Optimer platform can help. Whether you need an additional reagent to form an aptamer-antibody pair or…
Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…
DNA day on April 25th, celebrates major scientific achievements concerning DNA, in particular the completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix…
As SARS-CoV-2 continues to mutate we demonstrate the performance of
New research shows how Optimer can speed projects by up to 75% compared to standard antibodies. Speeding project timelines can be vital to the development of any life science product. Whether…
The genomic revolution brought simple, sensitive and rapid DNA sequencing, creating a step-change in our biological understanding. Next-generation proteomics is now promising to do the same for protein sequencing…
Anti-hapten antibodies are difficult and slow to generate limiting cheap and efficient bioanalysis in this field. Our proprietary methods offer standard assay formats, such as ELISA and lateral flow…
Antibiotic resistance is increasing globally and represents one of the biggest public health challenges of our time. In the US alone, there are more than 2.8 million cases of…
Researchers at the National Cancer Institute (Centro di Referimento Oncologico IRCCS), Aviano, Italy, have published a new paper in Analytical and Bioanalytical Chemistry. Using aptamers from Aptamer…